

Fusion Pharmaceuticals To Present At The 2021 Jefferies London Healthcare Conference

HAMILTON, Ontario and BOSTON, Nov. 11, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2021 Jefferies London Healthcare Conference. A recording of the presentation will be made available for on-demand viewing on Thursday, November 18, 2021 at 8:00am GMT. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

A webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at <https://ir.fusionpharma.com/events-webcasts>. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Fusion

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the recent investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRIs) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs.

SOURCE Fusion Pharmaceuticals Inc.

For further information: Fusion Contact: Amanda Cray, Senior Director of Investor Relations & Corporate Communications, 617-967-0207, cray@fusionpharma.com

<https://ir.fusionpharma.com/2021-11-11-Fusion-Pharmaceuticals-To-Present-At-The-2021-Jefferies-London-Healthcare-Conference>